Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 29;19(9):2568.
doi: 10.3390/ijms19092568.

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer

Melissa P Tan  1   2 , Gerhardt Attard  3 , Robert A Huddart  4   5
Affiliations
Review

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer

Melissa P Tan et al. Int J Mol Sci. .

Abstract

Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to muscle-invasive bladder cancer (MIBC), which is recognised to be a heterogeneous disease with overall poor prognosis. Using a range of platforms, studies have shown that ctDNA is detectable in MIBC and may be a useful biomarker in monitoring disease status and guiding treatment decisions in MIBC patients. Currently, with no such predictive or prognostic biomarkers in clinical practice to guide treatment strategy, there is a real unmet need for a personalised medicine approach in MIBC, and ctDNA offers an exciting avenue through which to pursue this goal. In this article, we present an overview of work to date on ctDNA in MIBC, and discuss the inherent challenges present as well as the potential future clinical applications.

Keywords: biomarker; circulating tumour DNA (ctDNA); muscle-invasive bladder cancer (MIBC).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

References

    1. Chan K.C., Jiang P., Zheng Y.W., Liao G.J., Sun H., Wong J., Siu S.S., Chan W.C., Chan S.L., Chan A.T., et al. Cancer genome scanning in plasma: Detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 2013;59:211–224. doi: 10.1373/clinchem.2012.196014. - DOI - PubMed
    1. Murtaza M., Dawson S.J., Pogrebniak K., Rueda O.M., Provenzano E., Grant J., Chin S.F., Tsui D.W., Marass F., Gale D., et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 2015;6:8760. doi: 10.1038/ncomms9760. - DOI - PMC - PubMed
    1. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., Diaz L.A., Jr., Goodman S.N., David K.A., Juhl H., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA. 2005;102:16368–16373. doi: 10.1073/pnas.0507904102. - DOI - PMC - PubMed
    1. Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., Dunning M.J., Gale D., Forshew T., Mahler-Araujo B., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013;368:1199–1209. doi: 10.1056/NEJMoa1213261. - DOI - PubMed
    1. Romanel A., Tandefelt D.G., Conteduca V., Jayaram A., Casiraghi N., Wetterskog D., Salvi S., Amadori D., Zafeiriou Z., Rescigno P., et al. Plasma AR abiraterone-resistant prostate cancer. Sci. Transl. Med. 2015;7:312. doi: 10.1126/scitranslmed.aac9511. - DOI - PMC - PubMed

LinkOut - more resources